Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Bone. 2020 Jun 23;138:115492. doi: 10.1016/j.bone.2020.115492

Figure 3. Differing effects of AP23451 and zoledronate on osteoclasts in metaphyses of mice inoculated with MDA-MB-231 breast cancer cells.

Figure 3.

(A). H&E-stained sections of distal femora of mice showing occasional surviving (yellow arrows) osteoclasts in AP23451-treated mice and surviving and apoptotic (black arrows) osteoclasts in zoledronate-treated mice. (B). Total numbers of osteoclasts in femoral metaphyses (left panel) and % of osteoclasts with the typical features of apoptosis (cytoplasmic contraction and nuclear condensation and fragmentation). Data are means +/− SD. One-way ANOVA with Bonferroni test. * p < 0.05 vs zoledronate.